Prudential PLC Has $382,000 Stake in Qiagen N.V. $QGEN

Prudential PLC decreased its stake in Qiagen N.V. (NYSE:QGEN) by 85.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,373 shares of the company’s stock after selling 49,125 shares during the quarter. Prudential PLC’s holdings in Qiagen were worth $382,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Massachusetts Financial Services Co. MA lifted its stake in Qiagen by 1.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 24,205,881 shares of the company’s stock valued at $1,088,538,000 after buying an additional 264,921 shares during the period. Vanguard Group Inc. lifted its stake in Qiagen by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,542,944 shares of the company’s stock valued at $433,871,000 after buying an additional 118,135 shares during the period. Amundi lifted its stake in Qiagen by 4.4% in the third quarter. Amundi now owns 4,290,273 shares of the company’s stock valued at $201,471,000 after buying an additional 181,509 shares during the period. Boston Partners acquired a new position in Qiagen in the third quarter valued at about $179,450,000. Finally, Norges Bank acquired a new position in Qiagen in the fourth quarter valued at about $166,500,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Down 1.1%

Shares of Qiagen stock opened at $36.28 on Tuesday. Qiagen N.V. has a 1 year low of $32.53 and a 1 year high of $57.81. The business has a 50-day moving average of $37.26 and a two-hundred day moving average of $44.31. The company has a market capitalization of $7.48 billion, a P/E ratio of 18.95, a price-to-earnings-growth ratio of 3.65 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.54. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The company had revenue of $492.32 million during the quarter, compared to the consensus estimate of $496.15 million. During the same period in the prior year, the company earned $0.56 earnings per share. As a group, equities analysts predict that Qiagen N.V. will post 2.43 EPS for the current year.

Qiagen Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be issued a dividend of $0.35 per share. The ex-dividend date is Tuesday, July 7th. This is a boost from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 104.0%. Qiagen’s dividend payout ratio is 13.61%.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Robert W. Baird set a $43.00 target price on Qiagen and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Weiss Ratings downgraded Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 29th. TD Cowen restated a “hold” rating and issued a $40.00 price target (down from $46.00) on shares of Qiagen in a report on Thursday, May 7th. Barclays set a $38.00 price target on Qiagen and gave the stock an “equal weight” rating in a report on Wednesday, April 29th. Finally, Zacks Research upgraded Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $44.98.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.